Generic placeholder image

Current Drug Metabolism


ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs

Author(s): Chiranjib Chakraborty, Minna J. Hsu and Govindasamy Agoramoorthy

Volume 16, Issue 10, 2015

Page: [864 - 876] Pages: 13

DOI: 10.2174/138920021610151210183821

Price: $65


The type 2 diabetes or T2D mellitus has turn into an epidemic throughout the globe in recent years. Various forms of treatment modalities have been available for patients with T2D with some major classes of approved drugs that include Sulfonylureas, Meglitinides, Biguanides, Thiazolidinedione, Alpha-glucosidase inhibitors, GLP-1 analogs, DPP-4 Inhibitors, and SGLT2 inhibitors. This review focuses on the drug metabolizing enzymes (DME), gene polymorphisms, and inter-individual variability in therapeutics including adverse reaction effects involving Phase-I DME and Phase-II in general. This review also covers some key anti-diabetic drugs with respect to their pharcogenomics.

Keywords: Asia, Diabetes, drugs, enzymes, pharcogenomics, T2D.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy